Study identifier:D3540C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A double blind randomised placebo-controlled crossover (single centre) study in healthy men (aged 18-45 years) to investigate the effect of multiple dosing (7 days bid) of inhaled AZD4818 at different dose levels on white blood cells and inflammatory markers in induced sputum and blood after oral inhalation of lipopolysaccharide (LPS)
Chronic Obstructive Pulmonary Disease
Phase 1
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|